CD24 as a Prognostic Marker in Lung Cancer
Author Information
Author(s): Kristiansen G, Schlüns K, Yongwei Y, Denkert C, Dietel M, Petersen I
Primary Institution: Charité University Hospital
Hypothesis
Is CD24 expression an independent prognostic marker of survival in nonsmall cell lung cancer patients?
Conclusion
CD24 expression is an independent predictor of shortened patient survival in nonsmall cell lung cancer.
Supporting Evidence
- CD24 expression was found in 76% of lung cancer cases examined.
- Patients with high CD24 expression had a median survival time of 23 months compared to 38 months for those with low expression.
- CD24 expression was significantly associated with tumor grading and disease stage.
Takeaway
This study found that a protein called CD24 can help doctors understand how long patients with lung cancer might live. If a patient has a lot of CD24, they might not live as long.
Methodology
The study used immunohistochemistry to evaluate CD24 expression in tumor samples from 89 patients with nonsmall cell lung cancer.
Limitations
The study only included patients who underwent surgery, excluding those with advanced metastatic disease.
Participant Demographics
Patients aged 34 to 80 years, mean age 62.
Statistical Information
P-Value
0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website